menu
    • menu

    Company profile for Myrobalan Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Myrobalan Therapeutics is a biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system (CNS) conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, along with innovative drug discovery tools, to create highly selec...
    Myrobalan Therapeutics is a biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and central nervous system (CNS) conditions. Myrobalan applies deep knowledge of neurological processes such as demyelination and neuroinflammation, along with innovative drug discovery tools, to create highly selective and brain-penetrant therapeutic candidates uniquely positioned for treating CNS conditions with significant unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Myrobalan TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Medford, MA 02155
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://myrotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/myrobalantx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Myrobalan Receives Grant to Develop MRO-002 for Multiple Sclerosis
    Myrobalan Receives Grant to Develop MRO-002 for Multiple Sclerosis

    13 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312951560/en/Myrobalan-Therapeutics-Awarded-a-Grant-from-the-National-Multiple-Sclerosis-Society-to-Advance-Development-of-MRO-002-in-Multiple-Sclerosis

    BUSINESSWIRE
    13 Mar 2025
    Share Share
    Myrobalan Appoints Robin Kleiman Ph.D. as Chief Scientific Officer
    Myrobalan Appoints Robin Kleiman Ph.D. as Chief Scientific Officer

    31 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241031361663/en

    BUSINESSWIRE
    31 Oct 2024
    Share Share
    Myrobalan Appoints Emma Reeve To Its Board Of Directors
    Myrobalan Appoints Emma Reeve To Its Board Of Directors

    16 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241010333901/en

    BUSINESSWIRE
    16 Oct 2024
    Share Share
    Myrobalan to present GPR17 antagonist preclinical data at ECTRIMS 2024
    Myrobalan to present GPR17 antagonist preclinical data at ECTRIMS 2024

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240918866628/en

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    Myrobalan Therapeutics Names Grant Bogle to Board of Directors
    Myrobalan Therapeutics Names Grant Bogle to Board of Directors

    29 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240725463217/en

    BUSINESSWIRE
    29 Jul 2024
    Share Share
    Myrobalan Receives a Grant to Advance its CSF1R Inhibitor Program
    Myrobalan Receives a Grant to Advance its CSF1R Inhibitor Program

    07 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240206866405/en

    BUSINESSWIRE
    07 Feb 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Myrobalan Wins Grant to Advance MRO-002 in Multiple Sclerosis Treatment

    Details:

    The funding aims to support the MRO-002 is an orally bioavailable, brain-penetrant, small molecule antagonist of GPR17. It is being evaluated for progressive multiple sclerosis.


    Lead Product(s): MRO-002

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Miscellaneous

    Sponsor: National Multiple Sclerosis Society

    Deal Size: $0.8 million Upfront Cash: Undisclosed

    Deal Type: Funding March 13, 2025

    blank

    01

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MRO-002

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : National Multiple Sclerosis Society

    Deal Size : $0.8 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Myrobalan Wins Grant to Advance MRO-002 in Multiple Sclerosis Treatment

    Details : The funding aims to support the MRO-002 is an orally bioavailable, brain-penetrant, small molecule antagonist of GPR17. It is being evaluated for progressive multiple sclerosis.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    March 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Myrobalan Therapeutics Receives Grant from ALS Association for CSF1R Inhibitor Program

    Details:

    The funding will be used to support the advancement of its colony-stimulating factor-1 receptor inhibitor for the treatment of amyotrophic lateral sclerosis.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Undisclosed

    Sponsor: ALS Association

    Deal Size: $0.4 million Upfront Cash: Undisclosed

    Deal Type: Funding February 07, 2024

    blank

    02

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : ALS Association

    Deal Size : $0.4 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Myrobalan Therapeutics Receives Grant from ALS Association for CSF1R Inhibitor Program

    Details : The funding will be used to support the advancement of its colony-stimulating factor-1 receptor inhibitor for the treatment of amyotrophic lateral sclerosis.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    February 07, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Myrobalan Completes $24 Million Series A Financing for CNS Therapeutics

    Details:

    Neurorestorative therapies, including a GPR17 antagonist, are in development as first-in-class orally available small molecule treatments.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Undisclosed

    Sponsor: Co-win Ventures

    Deal Size: $24.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing January 10, 2024

    blank

    03

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed

    Myrobalan Therapeutics

    U.S.A
    arrow
    Bioprocess International Europe
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Co-win Ventures

    Deal Size : $24.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Myrobalan Completes $24 Million Series A Financing for CNS Therapeutics

    Details : Neurorestorative therapies, including a GPR17 antagonist, are in development as first-in-class orally available small molecule treatments.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    January 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search